Figure 10.
Structures of plasmin inhibitors that show activities other than antifibrinolytic activity. Inhibitor 48 exhibits antitumor potential; SC 49 has been implicated in embryo implantation; Upamostat 50 is in pancreatic cancer Phase II studies; melagatran 51 was approved as a direct thrombin inhibitor; and H317/86 52, a benzamidine derivative related to upamostat, also inhibits plasmin. IC50 refers to inhibition of plasmin fibrinolysis.